Meeting
2018 ASCO Annual Meeting
FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.
Authors
Jeffrey S. Ross
SUNY Upstate Medical University, Syracuse, NY
Jeffrey S. Ross , Laurie M. Gay , Elizabeth Kate Ferry , Joseph Jacob , Oleg Shapiro , Jean H. Hoffman-Censits , Sherri Z. Millis , Julia Andrea Elvin , Jon Chung , Jo-Anne Vergilio , James Suh , Shakti H. Ramkissoon , Eric Allan Severson , Sugganth Daniel , Jonathan Keith Killian , Siraj Mahamed Ali , Alexa Betzig Schrock , Vincent A. Miller , Gennady Bratslavsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4531)
DOI
10.1200/JCO.2018.36.15_suppl.4531
Abstract #
4531
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes
Poster
2023 ASCO Genitourinary Cancers Symposium
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
First Author: Tanya Jindal
Poster
2018 ASCO Annual Meeting
PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.
First Author: Gennady Bratslavsky
Poster
2022 ASCO Annual Meeting
Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.
First Author: Gennady Bratslavsky